Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases

Leukemia Research

Volumn 39, Issue 3, 2015, Pages 348-354

  Ok, Chi Young ^a   Patel, Keyur P ^a   Garcia Manero, Guillermo ^a   Routbort, Mark J ^a   Fu, Bin ^a,b   Tang, Guilin ^a   Goswami, Maitrayee ^a   Singh, Rajesh ^a   Kanagal Shamanna, Rashmi ^a   Pierce, Sherry A ^a   Young, Ken H ^a   Kantarjian, Hagop M ^a   Medeiros, L Jeffrey ^a   Luthra, Rajyalakshmi ^a   Wang, Sa A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

AML; Karyotype; MDS; Next generation sequencing; Therapy related; TP53

Indexed keywords

APC PROTEIN; ATM PROTEIN; B RAF KINASE; CD135 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE 3A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EXPORTIN 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; JANUS KINASE 3; K RAS PROTEIN; NOTCH1 RECEPTOR; NUCLEOPHOSMIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN MLH1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; SMAD4 PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR EZH2; UVOMORULIN; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APC GENE; ARTICLE; CANCER RADIOTHERAPY; CARCINOMA; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DNMT3A GENE; FEMALE; FLT3 GENE; GENE MUTATION; GNAS GENE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IDH1 GENE; IDH2 GENE; INTERMETHOD COMPARISON; KARYOTYPE; KDR GENE; KIT GENE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEDULLOBLASTOMA; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; NEXT GENERATION SEQUENCING; NPM1 GENE; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PTPN11 GENE; RISK FACTOR; SARCOMA; TUMOR GENE; VERY ELDERLY; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROCEDURES; PROGNOSIS;

COHORT STUDIES; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS;

EID: 84924080017     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.12.006     Document Type: Article

References (34)

1. Vardiman J.W., Arber D.A., Brunning R.D., Larson R.A., Matutes E., Baumann I., et al. Therapy-related myeloid neoplasms. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 127-129. International Agency for Research on Cancer (IARC), Lyon. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
2. Greco M., D'Alo F., Scardocci A., Criscuolo M., Fabiani E., Guidi F., et al. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells, Mol, Dis 2010, 45:181-185.
3. Voso M.T., D'Alo F., Greco M., Fabiani E., Criscuolo M., Migliara G., et al. Epigenetic changes in therapy-related MDS/AML. Chem-Biol Interact 2010, 184:46-49.
4. Olney H.J., Le Beau M.M. The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Haematol 2001, 14:479-495.
5. Smith S.M., Le Beau M.M., Huo D., Karrison T., Sobecks R.M., Anastasi J., et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003, 102:43-52.
6. Zhou Y., Tang G., Medeiros L.J., McDonnell T.J., Keating M.J., Wierda W.G., et al. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol 2012, 25:237-245.
7. Ok C.Y., Hasserjian R.P., Fox P.S., Stingo F., Zuo Z., Young K.H., et al. Application of the International Prognostic Scoring System-Revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 2014, 28:185-189.
8. Walter M.J., Shen D., Shao J., Ding L., White B.S., Kandoth C., et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013, 27:1275-1282.
9. Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368:2059-2074.
10. Grossmann V., Schnittger S., Kohlmann A., Eder C., Roller A., Dicker F., et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012, 120:2963-2972.
11. Patel J.P., Gonen M., Figueroa M.E., Fernandez H., Sun Z., Racevskis J., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
12. Bejar R., Stevenson K.E., Caughey B.A., Abdel-Wahab O., Steensma D.P., Galili N., et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012, 30:3376-3382.
13. Shih A.H., Chung S.S., Dolezal E.K., Zhang S.J., Abdel-Wahab O.I., Park C.Y., et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica 2013, 98:908-912.
14. Pedersen-Bjergaard J., Andersen M.K., Andersen M.T., Christiansen D.H. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008, 22:240-248.
15. Junemann S., Sedlazeck F.J., Prior K., Albersmeier A., John U., Kalinowski J., et al. Updating benchtop sequencing performance comparison. Nat Biotechnol 2013, 31:294-296.
16. Robinson J.T., Thorvaldsdottir H., Winckler W., Guttman M., Lander E.S., Getz G., et al. Integrative genomics viewer. Nat Biotechnol 2011, 29:24-26.
17. Routbort M., Handal B., Patel K.P., Singh R., Aldape K., Reddy N., et al. OncoSeek: a versatile annotation and reporting system for next generation sequencing-based clinical mutation analysis of cancer specimens. AMP 2012 Meeting Abstract. J Mol Diagn 2012, 14:637-748. Abstract TT79.
18. Luthra R., Patel K.P., Reddy N.G., Haghshenas V., Routbort M.J., Harmon M.A., et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica 2014, 99:465-473.
19. Khoury J.D., Sen F., Abruzzo L.V., Hayes K., Glassman A., Medeiros L.J. Cytogenetic findings in blastoid mantle cell lymphoma. Hum Pathol 2003, 34:1022-1029.
20. Shaffer L.G., McGowan-Jordan J., Schmid M. An international system for human cytogenetic nomenclature 2013, S. Karger, Basel.
21. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
22. Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
23. Westman M.K., Pedersen-Bjergaard J., Andersen M.T., Andersen M.K. IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7)(q10;p10). Leukemia 2013, 27:957-959.
24. Haferlach T., Nagata Y., Grossmann V., Okuno Y., Bacher U., Nagae G., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014, 28:241-247.
25. Papaemmanuil E., Gerstung M., Malcovati L., Tauro S., Gundem G., Van Loo P., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122:3616-3627. quiz 99.
26. Walter M.J., Ding L., Shen D., Shao J., Grillot M., McLellan M., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25:1153-1158.
27. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
28. Thol F., Kade S., Schlarmann C., Loffeld P., Morgan M., Krauter J., et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012, 119:3578-3584.
29. Tartaglia M., Mehler E.L., Goldberg R., Zampino G., Brunner H.G., Kremer H., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001, 29:465-468.
30. Christiansen D.H., Desta F., Andersen M.K., Pedersen-Bjergaard J. Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations. Genes, Chromosomes Cancer 2007, 46:517-521.
31. Marcucci G., Haferlach T., Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29:475-486.
32. Martelli M.P., Sportoletti P., Tiacci E., Martelli M.F., Falini B. Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev 2013, 27:13-22.
33. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
34. Bacher U., Haferlach C., Alpermann T., Schnittger S., Kern W., Haferlach T. Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma 2013, 54:639-642.